MedWatch

Genmab drug becomes more accessible in the US

Tepezza, which Genmab developed under the ownership of Horizon Therapeutics, has now entered the portfolio of products offered through the largest group of independent specialty pharmacies in the US.

Photo: Jon Cherry/AFP / GETTY IMAGES NORTH AMERICA

Premier Pharmacy Services has now incorporated the Genmab-developed drug Tepezza in its product assortment, according to a press release from the pharmacy chain.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs